findmyKOL
Clinical trialNCT05451771Active, not recruitingPhase 1/PHASE2Interventional

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

SponsorColumbia UniversityEnrollment53AL Amyloidosis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Boston Medical Center

    Boston, Massachusetts, United States

  • Mayo Clinic Rochester

    Rochester, Minnesota, United States

  • Washington University School of Medicine

    St Louis, Missouri, United States

  • New York Presbyterian Hospital/columbia University Irving Medical Center

    New York, New York, United States

  • Froedtert Hospital & the Medical College of Wisconsin

    Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bendamustine →Daratumumab →Dexamethasone →Ixazomib →Pomalidomide →Venetoclax MTD with DexamethasoneVenetoclax →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 Oct 2022
Primary completion
30 Sept 2027
Completion
30 Sept 2027
Last update posted
10 Jul 2026
Registered enrollment
53
Registry id
NCT05451771
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.